• A New Indication of Secukinumab to be Approved in China! PharmaSources/Caicai
    April 26, 2020
    The marketing application (acceptance No. JXSS1900025) of a new indication of Novartis’ secukinumab in China has recently changed to “Under approval” and is expected to be approved soon. First approved by the NMPA for marketing in Mar. 2019, this will be
PharmaSources Customer Service